Debio 4326

Phase 3

DDebiopharm International SA

Debio 4326 is one of 6 therapeutic programs targeting Central precocious puberty. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Central Precocious PubertyActive, not recruiting

Central Precocious PubertyPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Central Precocious Puberty

#DrugCompanyPhaseTrials

Lupron

Sun Pharmaceutical Industries, Inc.

Approved

1 2

Leuprorelin

Takeda

Phase 3

4 3

Debio 025

DDebiopharm International SA

Phase 3

1 4

Debio 4326

DDebiopharm International SA

Phase 3

1 5

Gnrh Agonist

Johnson & Johnson

Preclinical

1 6

Enantone

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Central Precocious Puberty

NCT06129539

Clinical

Trials by Indication[1]

Central precocious puberty1 trial

LIBELULA™: An Open-label, Single-arm, Multi-center, Phase 3 Study on the Efficacy, Safety, and Pharmacokinetics of Debio 4326, a Triptorelin 12-month Formulation, in Pediatric Participants With Central Precocious Puberty

Active, not recruiting·DDebiopharm International SA·Phase 3·NCT06129539·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Debio 4326. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Debio 4326. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Debiopharm International SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: DDebiopharm International SA

Debio 4326

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Central precocious puberty1 trial

References

Drug Info

Quick Facts

Related News